发明名称 NEW CRYSTALLINE FORM OF N-(4-TRIFLUORMETHYLPHENYL)-5-METHYL-ISOXAZOLE-4-CARBOXAMID, PROCESS FOR ITS PREPARATION, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
摘要 Crystal modification 2 of N-(4-trifluoromethylphenyl)-5-met hylisoxazole-4-carboxamide (I) (leflunomid; HWA 486) is new. - New crystal modification 2 of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide (I) has lines (diffraction angles 2theta ([deg])) of strong intensity at 10.65, 14.20, 14.80, 16.10, 21.70, 23.15, 24.40, 24.85, 25.50, 25.85, 26.90 and 29.85 and of medium intensity at 7.40, 9.80, 13.10, 15.45, 16.80, 20.70, 21.45, 22.80, 23.85, 27.25 and 28.95 in the X-ray diffraction graph using Cu-Kalpha 1 radiation in the focusing Deybe-Scherrer procedure and transmission. Compound (I) is known from US 4284786. Independent claims are included for: (A) the preparation of crystal modification 2; and (B) the preparation of crystal modification 1 of compound (I) having lines of strong intensity at 16.70, 18.90, 23.00, 23.65 and 2.05 and lines of medium intensity at 8.35, 12.65, 15.00, 15.30, 18.35, 21.55, 24.10, 24.65, 25.45, 26.65, 27.40, 28.00 and 28.30 in the X-ray diffraction graph measured and defined in the same manner as for crystal modification 2. -
申请公布号 HU225870(B1) 申请公布日期 2007.11.28
申请号 HU19980001844 申请日期 1998.08.07
申请人 SANOFI-AVENTIS DEUTSCHLAND GMBH 发明人 FAASCH, HOLGER DR;HEDTMANN, UDO DR;PAULUS, ERICH DR;WESTENFELDER, UWE DR
分类号 C07D261/18;A61K31/42;A61P1/00;A61P3/08;A61P3/10;A61P11/00;A61P11/06;A61P13/02;A61P15/00;A61P17/00;A61P19/02;A61P25/00;A61P27/02;A61P27/14;A61P29/00;A61P31/04;A61P35/00;A61P37/00;A61P37/08;B01D9/02 主分类号 C07D261/18
代理机构 代理人
主权项
地址